Summary:
Introduction: Psoriasis is a chronic non-transmissible inflammatory dermatopathy that can be manifested at any age, affects both sexes equally and is characterized by a rapid and uneven proliferation of epidermal keratinocytes leading to the appearance of psoriatic plaques. According to modern research, psoriasis does not only affect the skin but is a systemic disease with cutaneous manifestations. It has been found that patients with psoriasis have a higher risk of developing other diseases that share common mechanisms of inflammation, like cardiovascular disease. The inflammatory reactions that occur in psoriasis can become a source of free radical production, increasing oxidative stress levels. The scope of this study was to examine the effect of treatment with biological factors on oxidative stress biomarkers, in patients with psoriasis.
Methods: 40 patients, women and men of various ages (median age 52 ± 14) with diagnosed plaque psoriasis were enrolled in the study. 26 patients were treated with a biological agent, such us IL-12 / IL-23 inhibitor, IL-17 inhibitor and tumor necrosis factor alpha (TNF-α) inhibitor. The remaining patients received topical or classical systemic therapy. Oxidative stress markers as protein carbonyls and malondialdehyde (MDA), were determined.
Results: TNF-α inhibition did not significantly affect protein carbonyl and MDA levels in patients who participated in the study (p>0.5). In contrast, after treatment with IL-12/23 inhibitors and IL-17 inhibitors, the concentration of protein carbonyls presented a tendency to reduction (13.1 ± 2.7 in the follow-up vs. 22.71 ± 5 in the baseline) while not affecting MDA levels (p>0.5).
